nasym
laboratorios hipra s.a. - v živo vidni goveja dihal syncytial virus (brsv), sev lym-56 - immunologicals za bovidae, govedo, Živo, virusna cepiva, goveje dihal syncytial virus (brsv) - govedo - aktivno imunizacijo goveda (za zmanjšanje virus prelivanje in dihal, klinične znake, ki jih povzročajo goveja dihal syncytial virus okužbe.
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - prašiči - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
suiseng diff/a
laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - prašiči - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.
trialdecal 70 mg tablete + 500 mg/800 i.e. filmsko obložene tablete
meda ab - alendronska kislina - tableta - alendronska kislina 70 mg / 1 tableta - alendronska kislina, kalcij in holekalciferol, zaporedni
karmustin tillomed pharma 100 mg prašek in vehikel za koncentrat za infundiranje
karmustin - prašek in vehikel za koncentrat za raztopino za infundiranje - karmustin 100 mg / 1 viala - karmustin
kabazitaksel teva 10 mg/ml koncentrat za raztopino za infundiranje
kabazitaksel - koncentrat za raztopino za infundiranje - kabazitaksel 10 mg / 1 ml - kabazitaksel
alvesco 160 mikrogramov inhalacijska raztopina pod tlakom
astrazeneca ab - ciklesonid - inhalacijska raztopina pod tlakom - ciklesonid 160 µg / 1 odmerek - ciklezonid
alvesco 80 mikrogramov inhalacijska raztopina pod tlakom
astrazeneca ab - ciklesonid - inhalacijska raztopina pod tlakom - ciklesonid 80 µg / 1 odmerek - ciklezonid
bimervax
hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - cepiva - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.
suiseng
laboratorios hipra -